RESEARCH MONOGRAPH · KDC-MN-344

Propofol

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

83/100

Workhorse intravenous anesthetic with weirder pharmacology than the textbooks let on

Propofol is the most-used IV anesthetic in the world for a reason. Fast on, fast off, redistributes out of the CNS in minutes, and the recovery profile is genuinely cleaner than thiopental or etomidate. Most clinicians treat it like a known quantity but the mechanism is still partly weird.

The standard story is GABA-A positive allosteric modulation, and yes, that's the dominant effect. But the binding site isn't the classical benzodiazepine site, and at clinical concentrations propofol also hits HCN1 channels, glycine receptors, and possibly modulates endocannabinoid signaling. The Hemmings group at Cornell and the Forman group have been picking this apart for years. It's a polypharmacology drug pretending to be a single-target one.

What we like as a research tool is that the pharmacokinetics are exceptionally well-characterized. Three-compartment models with known parameters, predictable context-sensitive half-time, easy to dose for steady-state CNS concentrations in animal work. Hard to overstate how useful that is when you want a controlled level of unconsciousness without messing up downstream measurements.

Sourcing-wise, the lipid emulsion formulation is what most people interact with. The active is straightforward 2,6-diisopropylphenol, but the emulsion (soybean oil, egg lecithin, glycerol) is where most QC issues live. Bacterial contamination risk in opened vials is a real thing. For research, the pure active is preferable when you're not constrained to clinical formulation.

What we dont like is how often propofol gets framed as benign. Propofol infusion syndrome is real, hemodynamic depression is dose-dependent, and the metabolic and mitochondrial effects at high cumulative doses are nontrivial. Theres also the lipid load issue with prolonged infusions, easy to forget.

For neuroscience research, the EEG signatures (alpha coherence, slow-delta) are some of the best-characterized markers of pharmacologically induced unconsciousness we have. The Brown lab work at MIT (alpha-thalamocortical loop) is required reading if you're doing anything in this space.

Honestly the most interesting recent angle is propofol's potential glymphatic and neuroinflammatory effects, plus the steady accumulation of evidence around propofol-induced developmental neurotoxicity in young animal models. Not a settled question.

Evidence: 92
Mechanism: 80
Reliability: 90
Safety: 70
Sourcing: 82
Value: 75
Signal: 85
Staying power: 90

Plain-language summary Intrigue 60 / 100

Propofol is the workhorse intravenous induction anesthetic used in most operating rooms and procedural sedation suites in the world. It enhances GABA-A receptor signaling at a unique binding site and produces rapid loss of consciousness within seconds of injection, with quick recovery as the milky lipid emulsion redistributes from brain to fat. It is also famous, unfortunately, as the agent involved in Michael Jackson's 2009 death from physician-administered home use. The drug has a narrow therapeutic margin between sedation and respiratory arrest, which is why it is restricted to clinicians trained in airway management. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

GABA-A receptor positive allosteric modulator (intravenous anesthetic)

An alkylphenol intravenous general anesthetic; the most widely used induction anesthetic and the agent in Michael Jackson's death.

Abstract

Propofol (2,6-diisopropylphenol; CAS 2078-54-8; molecular formula C12H18O; molecular weight 178.27) is an alkylphenol intravenous general anesthetic developed at ICI (now AstraZeneca) and approved by the FDA in 1989 (Diprivan). The compound is a GABA-A receptor positive allosteric modulator at a unique propofol-binding site distinct from the benzodiazepine, barbiturate, and steroid sites; the result is enhanced GABA-mediated chloride conductance and pronounced CNS depression. Formulation is a 1 percent oil-in-water emulsion (the source of the milky appearance). Plasma half-life is biphasic: rapid distribution (2 to 4 minutes) and slower elimination (3 to 12 hours). Approved indications: induction and maintenance of general anesthesia, sedation in ICU. Misuse for amateur sedation is associated with the death of Michael Jackson (2009). Propofol infusion syndrome (rare) involves metabolic acidosis, rhabdomyolysis, and cardiac failure with prolonged high-dose use. Used as the canonical IV anesthetic in research and clinical practice.

Mechanism of action

GABA-A receptor positive allosteric modulator at a unique propofol-binding site; enhances GABA-mediated chloride conductance.

Reported research dose ranges

Clinical induction 1.5 to 2.5 mg/kg IV; maintenance 4 to 12 mg/kg/hour.

References

Kotani Y, et al. The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties. CNS Neurosci Ther 2008.
Trapani G, et al. Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem 2000.
Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia 2007.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-344

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Propofol

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs